INDUSTRY

New Aimovig Medication Approved

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 New Aimovig Medication Approved Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. […]

New Aimovig Medication Approved Read More »

Novartis’ Migraine prevention therapy is closer to being approved

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes

Novartis’ Migraine prevention therapy is closer to being approved Read More »

First monoclonal antibody therapy for prevention of migraine

First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity

First monoclonal antibody therapy for prevention of migraine Read More »

Cluster headache: Galcanezumab

Cluster headache: Galcanezumab Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks. In weekly clusters compared to placebo during the weeks

Cluster headache: Galcanezumab Read More »

CGRP as the target of new migraine therapies

CGRP as the target of new migraine therapies — successful translation from bench to clinic You can now download the document here:  —–>  CGRP as the target of new migraine therapies — successful translation from bench to clinic Treatment of migraine is on the cusp of a new era with the development of drugs that target

CGRP as the target of new migraine therapies Read More »

New measures to avoid valproate exposure in pregnancy

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar

New measures to avoid valproate exposure in pregnancy Read More »

Scroll to Top
Search
Close this search box.